Asia (including Southeast Asia, China, and India) India – CDSCO/SEC pauses Bharat Biotech MTBVAC Phase III authorisation (6 June 2026) India’s Subject Expert Committee identified data gaps and a serious adverse event in Bharat Biotech’s MTBVAC Phase II submission and ordered a detailed laboratory investigation before authorising a pivotal Phase III trial of this live-attenuated BCG-replacement TB vaccine candidate. The decision indefinitely delays what had been one of the world’s most advanced TB vaccine programmes. India – Professional societies promote simplified 2026 adult immunisation schedule (GNN/ViVa, 1 June 2026) India’s immunisation community highlighted 2026 adult guidance incorporating PCV20, positioning adult vaccination, including cancer-prevention vaccines (HPV), as a core preventive strategy, aligned with UIP gains showing rotavirus coverage rising from 36.4% to 85.4% and measles 2nd-dose coverage increasing to 71.8%. Hong Kong SAR – CHP/DH issues LP.8.1 COVID-19 vaccine stock-expiry notice (2 June 2026) The Centre for Health Protection formally advised that government-supplied COVID-19 vaccines...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!
